Stryker Unit Charged With Fraud, Misbranding For Illegal Marketing Scheme

Stryker's biotech division and four former and current executives face charges of wire fraud, conspiracy, device misbranding and false statements related to the marketing of its OP-1 orthopedic bone growth biologic/device combination products